The Therapeutic Goods Administration (TGA) has proposed banning or suspending the use of high-grade textured breast implants because of their links to the rare cancer.

The proposed ban would remove access to products that make up about 45 per cent of Australia's breast implant market.

Over 100,000 Australian women are estimated to be walking around with implants linked to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

The TGA has focused on nine products made by Allergan, including Natrelle Truform, Soft touch and Inspira, as well as products including Adirel Nagor, Emagin, Emergo, Euro Implants, JT medical, and Johnson & Johnson's siltex products.

“No decision has been made to suspend or cancel the relevant products at this time,” the TGA said in a statement.

“The TGA is required by law to provide the sponsors of affected implants with an opportunity to make submissions in response to proposed regulatory action.

“The TGA will then take into consideration each sponsor's submission when deciding what, if any, regulatory action should be taken in relation to a particular sponsor's device.”

Breast implant makers and distributors have until July 24 to respond to the TGA’s proposals.